As US da­ta for Covid-19 vac­cine loom, As­traZeneca cleans house and scraps sev­er­al asth­ma, can­cer drugs from pipeline

Just a week af­ter re­veal­ing an­oth­er flop for its PD-1/CT­LA-4 strat­e­gy, As­traZeneca has scrapped plans for the Imfinzi/treme­li­mum­ab com­bo in head and neck can­cer.

Sev­er­al oth­er ear­ly- to mid-stage pro­grams are al­so be­ing swept out as Pas­cal So­ri­ot con­sol­i­dates the pipeline around can­cer, car­dio­vas­cu­lar and meta­bol­ic dis­eases while prep­ping the roll­out of both its vac­cine and an­ti­body treat­ments for Covid-19 — with a read­out of its US vac­cine tri­al due in the first quar­ter of the year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER